Siltuximab
From Wikipedia, the free encyclopedia
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (mouse/human) |
| Target | IL-6 |
| Clinical data | |
| Legal status | Investigational |
| Identifiers | |
| CAS number | 541502-14-1  |
| ATC code | None |
| UNII | T4H8FMA7IM  |
| Synonyms | CNTO 328 |
| Chemical data | |
| Formula | C6450H9932N1688O2016S50 |
| Mol. mass | 145.0 kDa |
| (what is this?) (verify) | |
Siltuximab (INN) (also known as CNTO 328, Anti-IL-6 chimeric monoclonal antibody or cCLB8) is a chimeric (made from human and mouse proteins) monoclonal antibody. It binds to interleukin-6.[1] Siltuximab has been investigated for the treatment of metastatic renal cell cancer,[2] prostate cancer,[3] and Castleman's disease,[4][5] among other types of cancer.[6]
It has undergone a phase I clinical trial in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease.[7]
It gave encouraging results in a small trial for advanced ovarian cancer.[8]
Encouraging results have been reported from a phase II trial for relapsed or refractory multiple myeloma.[9]
References
- ↑ International Nonproprietary Names for Pharmaceutical Substances (INN, prepublication copy), World Health Organization.
- ↑ Rossi, J. -F.; Négrier, S.; James, N. D.; Kocak, I.; Hawkins, R.; Davis, H.; Prabhakar, U.; Qin, X.; Mulders, P.; Berns, B. (2010). "A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer". British Journal of Cancer 103 (8): 1154–1162. doi:10.1038/sj.bjc.6605872. PMC 2967052. PMID 20808314.
- ↑ Karkera, J.; Steiner, H.; Li, W.; Skradski, V.; Moser, P. L.; Riethdorf, S.; Reddy, M.; Puchalski, T.; Safer, K.; Prabhakar, U.; Pantel, K.; Qi, M.; Culig, Z. (2011). "The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study". The Prostate 71 (13): 1455–1465. doi:10.1002/pros.21362. PMID 21321981.
- ↑ Van Rhee, F.; Fayad, L.; Voorhees, P.; Furman, R.; Lonial, S.; Borghaei, H.; Sokol, L.; Crawford, J.; Cornfeld, M.; Qi, M.; Qin, X.; Herring, J.; Casper, C.; Kurzrock, R. (2010). "Siltuximab, a Novel Anti-Interleukin-6 Monoclonal Antibody, for Castleman's Disease". Journal of Clinical Oncology 28 (23): 3701–3708. doi:10.1200/JCO.2009.27.2377. PMID 20625121.
- ↑ First IL-6–blocking drug nears approval for rare blood disorder Nature Medicine, October 7, 2013
- ↑ ClinicalTrials.gov: Siltuximab
- ↑ "A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease".
- ↑ "CNTO 328 Shows Promise For Ovarian Cancer In Small Clinical Trial, Say U.K. Scientists.". 2009.
- ↑ "A phase II multicenter study of CNTO 328, an anti-IL-6 monoclonal antibody, in patients (pts) with relapsed or refractory multiple myeloma (MM)". 2009.
This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.